Actively Recruiting
A Study in Patients With Advanced Cancers
Led by BiOneCure Therapeutics Inc. · Updated on 2022-07-19
332
Participants Needed
3
Research Sites
261 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers.
CONDITIONS
Official Title
A Study in Patients With Advanced Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically or cytologically confirmed locally advanced or metastatic solid tumor
- Disease progression after standard treatment or refractory solid tumors not tolerating standard treatment
- Measurable disease by RECIST v.1.1 or bone-only disease
- ECOG performance status of 0 or 1
You will not qualify if you...
- History of severe hypersensitivity to any study drug ingredient including pembrolizumab or other monoclonal antibodies
- Impaired cardiac function or significant cardiac disease history
- Infection with HIV, active hepatitis B or C
- Active SARS-CoV-2 infection
- Untreated central nervous system tumor, epidural tumor or brain metastasis
- Other protocol-defined exclusion criteria may apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
NEXT Oncology Austin
Austin, Texas, United States, 78758
Actively Recruiting
2
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
3
NEXT Oncology Virginia
Fairfax, Virginia, United States, 22031
Actively Recruiting
Research Team
B
BiOneCure Therapeutics Inc.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here